Investors have hammered Sarepta in anticipation of a negative FDA review of its drug to treat Duchenne muscular dystrophy. But despite the latest delay due to weather, the company’s supporters refuse to back down.

from Forbes – Tech http://ift.tt/1QgsW0a
via IFTTT